| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | barasertib | CTRPv2 | pan-cancer | AAC | 0.079 | 0.01 |
| mRNA | PLX4720 | CCLE | pan-cancer | AAC | -0.12 | 0.01 |
| mRNA | TAE684 | GDSC1000 | pan-cancer | AAC | -0.13 | 0.01 |
| mRNA | MK-2206 | CTRPv2 | pan-cancer | AAC | 0.087 | 0.01 |
| mRNA | MLN4924 | GDSC1000 | pan-cancer | AAC | -0.1 | 0.01 |
| mRNA | Bexarotene | GDSC1000 | pan-cancer | AAC | -0.091 | 0.02 |
| mRNA | Vorinostat | GDSC1000 | pan-cancer | AAC | 0.08 | 0.02 |
| mRNA | RO-3306 | GDSC1000 | pan-cancer | AAC | -0.089 | 0.02 |
| mRNA | UNC0638:navitoclax (1:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.086 | 0.02 |
| mRNA | AKT inhibitor VIII | GDSC1000 | pan-cancer | AAC | -0.086 | 0.02 |